Health Systems Product News

Published Online: Sunday, March 1, 2009

Sumatriptan Succinate Injection

Sandoz (Princeton, NJ) recently introduced Sumatriptan Succinate Injection. The product is the generic equivalent of GlaxoSmithKline?s Imitrex. Sumatriptan Succinate Injection is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. The product is not for use in the management of hemiplegic or basilar headache. The maximum single recommended adult dose of Sumatriptan Succinate Injection is 6 mg injected subcutaneously. The maximum recommended dose that may be given in 24 hours is two 6-mg injections separated by at least 1 hour. Each 0.5 mL of Sumatriptan Succinate Injection 12-mg/ mL solution contains 6 mg of sumatriptan (base) as the succinate salt and is supplied as a clear, colorless to pale yellow, sterile, nonpyrogenic solution in the following packs: two 6-mg single-dose prefilled syringe cartridges with a patient information leaflet with instructions for use and a single-dose vial in cartons containing 5 vials. For more information, visit www.us.sandoz.com.


Nexterone (amiodarone HCl) Injection

Prism Pharmaceuticals Inc (King of Prussia, PA) recently received FDA approval for its new drug application for Nexterone. The product is an antiarrhythmic agent indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy. Nexterone also can be used to treat patients with VT/VF for whom oral amiodarone is indicated, but who are unable to take oral medication. The recommended starting dose of Nexterone is about 1000 mg over the first 24 hours of therapy. Nexterone is available in single-use glass vials packaged in individual cartons of 150 mg/3 mL in a 5-mL vial, 450 mg/9 mL in a 10-mL vial, and 900 mg/18 mL in a 20-mL vial. The product also is available in single-use glass prefilled syringes packaged in blister packs of 150 mg/3 mL in a 5-mL prefilled syringe. For more information, visit www.prismpharma.com.



Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues
$auto_registration$
VSEO N/A